Introduction & remarks.

Event : Heart Failure 2017

• Session : Management of co-morbidities in heart failure - Exploring new frontiers
• Speaker : N Danchin (Montreuil,FR)

• Sponsored by Bayer AG

Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

Event : Heart Failure 2017

• Session : Management of co-morbidities in heart failure - Exploring new frontiers
• Speaker : M Cowie (London,GB)

• Sponsored by Bayer AG

Options in thrombosis prevention and vascular health – What’s on the horizon?

Event : Heart Failure 2017

• Session : Management of co-morbidities in heart failure - Exploring new frontiers
• Speaker : K Fox (Edinburgh,GB)

• Sponsored by Bayer AG

Broadening the evidence base for rivaroxaban in heart failure.

Event : Heart Failure 2017

• Session : Management of co-morbidities in heart failure - Exploring new frontiers
• Speaker : B Greenberg (La Jolla,US)

• Sponsored by Bayer AG

Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?

Event : Heart Failure 2017

• Session : Management of co-morbidities in heart failure - Exploring new frontiers
• Speaker : R Mentz (Durham,US)

• Sponsored by Bayer AG

Q&A and closing remarks.

Event : Heart Failure 2017

• Session : Management of co-morbidities in heart failure - Exploring new frontiers
• Speaker : M Cowie (London,GB)

• Sponsored by Bayer AG